Adverse effects of low-dose systemic cyclosporine therapy in high-risk penetrating keratoplasty

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 253, Issue 7, 2015, Pages 1111-1119

  Lee, Jong Joo ^a   Kim, Mee Kum ^b,c   Wee, Won Ryang ^b,c  

^a Chungnam National University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Adverse effects; Cornea; Cyclosporine; Herpes keratitis; Hypertension; Penetrating keratoplasty

Indexed keywords

ACECLOFENAC; ACICLOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; CYCLOSPORIN A; GANCICLOVIR; GLUCOSE; PREDNISOLONE; PREDNISOLONE ACETATE; SIMVASTATIN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC GRAFT REJECTION; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; GRAFT SURVIVAL; HEARTBURN; HERPES SIMPLEX KERATITIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRICHOSIS; INDIGESTION; KOREAN (PEOPLE); LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUTROPHIL COUNT; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SIDE EFFECT; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT DURATION; VASCULARIZATION; DRUG EFFECTS; FOLLOW UP; IATROGENIC DISEASE; KERATITIS, HERPETIC; MIDDLE AGED; OPPORTUNISTIC INFECTIONS;

ADOLESCENT; ADULT; AGED; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; HYPERTENSION; IATROGENIC DISEASE; IMMUNOSUPPRESSIVE AGENTS; KERATITIS, HERPETIC; KERATOPLASTY, PENETRATING; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES;

EID: 84933181977     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-015-3008-0     Document Type: Article

References (37)

1. Hamrah P, Mantopoulos D, Akhtar J, Djalilian AR (2011) Immunologically high-risk penetrating keratoplasty. In: Krachmer JH, Mannis MJ, Holland EJ (eds) Cornea, vol 2, 3rd edn. Elsevier/Mosby, Philadelphia, pp 1495–1509
2. Reis A, Reinhard T (2010) New developments in topical and systemic immunomodulation following penetrating keratoplasty. In: Reinhard T, Larkin F (eds) Cornea and external eye disease. Springer, Germany, pp 25–37
3. Uusitalo RJ, Mahlberg K, Krootila K, Ruusuvaara P (1996) Systemic cyclosporin treatment for high-risk corneal transplantation. Ocul Immunol Inflamm 4(1):15–24. doi:10.3109/09273949609069123
4. Hill JC (1995) Systemic cyclosporine in high-risk keratoplasty: long-term results. Eye (Lond) 9(Pt 4):422–428. doi:10.1038/eye.1995.99
5. Hill JC (1994) Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. Ophthalmology 101(1):128–133
6. Chong EM, Dana MR (2008) Graft failure IV. Immunologic mechanisms of corneal transplant rejection. Int Ophthalmol 28(3):209–222. doi:10.1007/s10792-007-9099-9
7. Reinhard T, Sundmacher R, Heering P (1996) Systemic ciclosporin A in high-risk keratoplasties. Graefes Arch Clin Exp Ophthalmol 234(Suppl 1):S115–S121
8. Poon AC, Forbes JE, Dart JK, Subramaniam S, Bunce C, Madison P, Ficker LA, Tuft SJ, Gartry DS, Buckley RJ (2001) Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study. Br J Ophthalmol 85(12):1464–1469
9. Inoue K, Kimura C, Amano S, Sato T, Fujita N, Kagaya F, Kaji Y, Tsuru T, Araie M (2001) Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty. Jpn J Ophthalmol 45(4):378–382
10. Rumelt S, Bersudsky V, Blum-Hareuveni T, Rehany U (2002) Systemic cyclosporin A in high failure risk, repeated corneal transplantation. Br J Ophthalmol 86(9):988–992
11. Shimazaki J, Den S, Omoto M, Satake Y, Shimmura S, Tsubota K (2011) Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Ophthalmol 152(1):33–39. doi:10.1016/j.ajo.2011.01.019, e1
12. Djalilian AR, Bhasin AK, Holland EJ (2011) Postoperative management of ocular surface reconstruction. In: Krachmer JH, Mannis MJ, Holland EJ (eds) Cornea, 3rd edn. Elsevier/Mosby, Philadelphia, pp 1745–1753
13. Birnbaum F, Bohringer D, Sokolovska Y, Sundmacher R, Reinhard T (2005) Immunosuppression with Cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplantation 79(8):964–968. doi:10.1097/01.tp.0000158022.62059.f2
14. Maier AK, Ozlugedik S, Rottler J, Heussen FM, Klamann MK, Huber KK, Joussen AM, Winterhalter S (2011) Efficacy of postoperative immunosuppression after keratoplasty in herpetic keratitis. Cornea 30(12):1398–1405. doi:10.1097/ICO.0b013e31821e65b3
15. Garcia DD, Farjo Q, Musch DC, Sugar A (2007) Effect of prophylactic oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Cornea 26(8):930–934. doi:10.1097/ICO.0b013e3180e79b77
16. Jansen AF, Rijneveld WJ, Remeijer L, Volker-Dieben HJ, Eggink CA, Geerards AJ, Mulder PG, van Rooij J (2009) Five-year follow-up on the effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis. Cornea 28(8):843–845. doi:10.1097/ICO.0b013e318198399a
17. Lomholt JA, Baggesen K, Ehlers N (1995) Recurrence and rejection rates following corneal transplantation for herpes simplex keratitis. Acta Ophthalmol Scand 73(1):29–32
18. Graham RM (1994) Cyclosporine: mechanisms of action and toxicity. Cleve Clin J Med 61(4):308–313
19. Johnson AJ, Chu CF, Milligan GN (2008) Effector CD4+ T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords. J Virol 82(19):9678–9688. doi:10.1128/JVI. 01159-08
20. Nakanishi Y, Lu B, Gerard C, Iwasaki A (2009) CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462(7272):510–513. doi:10.1038/nature08511
21. Reinhard T, Reis A, Böhringer D, Malinowski M, Voiculescu A, Heering P, Godehardt E, Sundmacher R (2001) Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years’ results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol 239(5):367–372. doi:10.1007/s004170100285
22. Sander M, Lyson T, Thomas GD, Victor RG (1996) Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens 9(11):121S–138S
23. Taler SJ, Textor SC, Canzanello VJ, Schwartz L (1999) Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf 20(5):437–449
24. Gaston RS (2001) Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 38(6 Suppl 6):S25–S35
25. Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, Jouanneau C, Jaudon MC, Maksud P, Mallet A, LeHoang P, Deray G (2002) Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol 13(12):2962–2968
26. Naesens M, Kuypers DR, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4(2):481–508. doi:10.2215/CJN.04800908
27. Tedesco D, Haragsim L (2012) Cyclosporine: a review. J Transplant 2012, 230386. doi:10.1155/2012/230386
28. Perez de Hornedo J, de Arriba G, Calvino M, Benito S, Parra T (2007) Cyclosporin A causes oxidative stress and mitochondrial dysfunction in renal tubular cells. Nefrologia 27(5):565–573
29. Naughton CA (2008) Drug-induced nephrotoxicity. Am Fam Physician 78(6):743–750
30. Xu W, Fan W, Yao K (2012) Cyclosporine A stimulated hair growth from mouse vibrissae follicles in an organ culture model. J Biomed Res 26(5):372–380. doi:10.7555/JBR.26.20110067
31. Gafter-Gvili A, Sredni B, Gal R, Gafter U, Kalechman Y (2003) Cyclosporin A-induced hair growth in mice is associated with inhibition of calcineurin-dependent activation of NFAT in follicular keratinocytes. Am J Physiol Cell Physiol 284(6):C1593–1603. doi:10.1152/ajpcell.00537.2002
32. Weibrecht K, Dayno M, Darling C, Bird SB (2010) Liver aminotransferases are elevated with rhabdomyolysis in the absence of significant liver injury. J Med Toxicol 6(3):294–300. doi:10.1007/s13181-010-0075-9
33. Lasocki A, Vote B, Fassett R, Zamir E (2007) Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis. Ocul Immunol Inflamm 15(4):345–346. doi:10.1080/09273940701375147
34. Maxa JL, Melton LB, Ogu CC, Sills MN, Limanni A (2002) Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann Pharmacother 36(5):820–823
35. Pleyer U (2003) Immunomodulation in penetrating keratoplasty. Current status and perspectives. Ophthalmologe 100(12):1036–1044. doi:10.1007/s00347-003-0954-4
36. Birnbaum F, Mayweg S, Reis A, Bohringer D, Seitz B, Engelmann K, Messmer EM, Reinhard T (2009) Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study. Eye (Lond) 23(11):2063–2070. doi:10.1038/eye.2008.402
37. Chatel MA, Larkin DF (2010) Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk. Am J Ophthalmol 150(2):179–184. doi:10.1016/j.ajo.2010.03.010